AbbVie stock had its Relative Strength (RS) Rating upgraded from 69 to 76 Thursday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks often have an RS Rating of at least 80 in the early stages of their moves. See if AbbVie stock can continue to rebound and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Is AbbVie Stock A Buy?
AbbVie stock is building a saucer with handle with a 168.21 entry. See if it can clear the breakout price in volume at least 40% above average.
The drugmaker showed 17% earnings growth last quarter. Revenue gains came in at 2%. Look for the next report on or around Apr. 27.
AbbVie stock holds the No. 4 rank among its peers in the Medical-Ethical Drugs industry group. Sanofi ADR and AbbVie are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
